Pharmaceutical company R&D productivity has continued to be a topic of concern among industry analysts. Recent pricing and regulatory developments, such as the Inflation Reduction Act in the US and anticipated changes to exclusivity periods in the EU, may exacerbate this further. As pressure increases on R&D investment returns, acting to improve R&D efficiency is an industry imperative.
This white paper explores the importance of R&D success rates and attrition profiles and highlights the ways in which companies can act on these to maximize the efficiency and productivity of their R&D functions, while avoiding several important pitfalls.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Decrease clinical development costs and increase study quality using our global functional resources and flexible services, and get more value from your R&D spend.
Solutions for you to drive healthcare forward™
.svg){kind=icon}
